Soon, in 1994, ICOS accepted a patent for deepen IC351 (structurally different sildenafil citrate and vardenafil), and Phase angle 1 clinical trials began in 1995. In 1997, the Stage 2 clinical studies were initiated for males experiencing ED, then progressed to the Phase 3 trials that supported the drug's FDA approving. Deuce age later, Lilly ICOS, LLC, filed a fresh drug applications programme with the Food and Drug Administration for compound IC351 (nether the Cialis generic name, and the C...
4 views
0 likes